Q-omics provides the consensus-scored RPL36AP29 profile across patient tissues and cancer cell-line models. RPL36AP29 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPL36AP29 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, RPL36AP29 RNA expression shows 10,030 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, KICH, and GBM as cancer lineages where RPL36AP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AP29 survival associations across molecular data types. RPL36AP29 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AP29 RNA expression–survival associations across cancer types. High RPL36AP29 expression shows unfavorable associations in THCA, ACC, STAD and MESO, but favorable associations in CHOL and HNSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RPL36AP29 RNA expression.
This table summarizes RPL36AP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36AP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AP29 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC and LIHC. The KICH box plot shows higher RPL36AP29 RNA expression in normal versus tumor tissue (log2 FC = −0.312, t-test p < 0.001).
This table shows molecular features associated with RPL36AP29 in patient tissues and cancer cell lines. In patient samples, RPL36AP29 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
